{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:04:45Z","timestamp":1753891485226,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Headache is frequently reported as a neurological manifestation of myeloproliferative neoplasms (MPNs), including polycythemia vera and essential thrombocythaemia. This study sought to clarify the clinical characteristics and response to treatment of headaches in patients with MPNs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively studied 137 patients with MPNs. The following information was gathered to assess the features of headache at baseline and at follow-up (&amp;gt;6 months): (1) average duration of headache attacks, (2) number of headache days per month, (3) numerical rating scale (NRS), (4) Headache Impact Test-6 (HIT-6), and (5) Migraine Disability Assessment (MIDAS). We compared those parameters for headaches between the baseline and follow-up interviews according to the management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty-seven (27.0%) patients had headache. The prevalence of headaches gradually decreased with increasing age (Age \u2264 49 years: 61.0%, 50\u201359 years: 38.5%, 60\u201369 years: 17.2%, 70\u201379 years: 5.1%, and \u226580 years: 0.0%, <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Multiple logistic regression analysis showed that younger age, but not platelet counts or the <jats:italic>JAK2<\/jats:italic> V617F mutation, was independently associated with headaches (Odds Ratios 2.004, 95% confidence intervals 1.293\u20133.108, <jats:italic>P<\/jats:italic> = 0.002). Scintillating scotomas were present in 22 (59.5%) of 37 patients with headaches, while four patients developed sudden headaches that lasted for only 0\u201310 min. Follow-up interviews were available for 31 (83.8%) of 37 patients with headaches. Twenty-one (67.7%) patients were treated with low-dose aspirin (100 mg once daily) [low-dose aspirin alone: <jats:italic>n<\/jats:italic> = 9; combined cytoreductive therapy: <jats:italic>n<\/jats:italic> = 12] for headache management. All parameters for headache [average duration of headache attacks, number of headache days per month, NRS score, HIT-6 score, and MIDAS score (all <jats:italic>P<\/jats:italic> &amp;lt; 0.001)] were significantly improved at follow-up in patients taking low-dose aspirin. However, there were no significant differences in these parameters of headaches in patients who did not receive low-dose aspirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Headaches is common in patients with MPNs, particularly in younger patients. MPN-related headaches may be managed by using low-dose aspirin and controlling MPNs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1051093","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:09:55Z","timestamp":1670328595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characteristics and management of headache in patients with myeloproliferative neoplasms"],"prefix":"10.3389","volume":"13","author":[{"given":"Takashi","family":"Shimoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"GBD","year":"2018","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjmed.2009.12.021","article-title":"Migraine headache and ischemic stroke risk: an updated meta-analysis","volume":"123","author":"Spector","year":"2010","journal-title":"Am J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacc.2020.11.068","article-title":"Pooled analysis of PFO occluder device trials in patients with PFO and migraine","volume":"77","author":"Mojadidi","year":"2021","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/03331024211068065","article-title":"NCOR2 is a novel candidate gene for migraine-epilepsy phenotype","volume":"42","author":"Nuottamo","year":"2022","journal-title":"Cephalalgia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study","volume":"21","author":"Buse","year":"2020","journal-title":"J Headache Pain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/head.13435","article-title":"Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study","volume":"59","author":"Buse","year":"2019","journal-title":"Headache."},{"key":"B8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-019-1016-x","article-title":"Aura and Stroke: relationship and what we have learnt from preclinical models","volume":"20","author":"Yemisci","year":"2019","journal-title":"J Headache Pain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms; a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1007\/s00415-021-10441-9","article-title":"Cerebrovascular manifestations in hematological diseases: an update","volume":"268","author":"Ferro","year":"2021","journal-title":"J Neurol."},{"key":"B16","first-page":"537","article-title":"Essential thrombocythemia: a retrospective study on the clinical course of 100 patients","volume":"75","author":"Chistolini","year":"1990","journal-title":"Haematologica."},{"key":"B17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","article-title":"Clinical course of essential thrombocythemia in 147 cases","volume":"66","author":"Fenaux","year":"1990","journal-title":"Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.43.6.1107","article-title":"Transient neurologic and ocular manifestations in primary thrombocythemia","volume":"43","author":"Michiels","year":"1993","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-2007-996110","article-title":"Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin","volume":"23","author":"Koudstaal","year":"1997","journal-title":"Semin Thromb Hemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1742-1241.2012.02986.x","article-title":"Headache in essential thrombocythaemia","volume":"66","author":"Frewin","year":"2012","journal-title":"Int J Clin Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3324\/haematol.2011.050005","article-title":"Neurological disorders in essential thrombocythemia","volume":"96","author":"Billot","year":"2011","journal-title":"Haematologica."},{"key":"B23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jns.2016.04.014","article-title":"Aspirin, but not clopidogrel, ameliorates vasomotor symptoms due to essential thrombocythemia: a case report","volume":"365","author":"Sakamoto","year":"2016","journal-title":"J Neurol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jama.2015.8515","article-title":"Thrombocytosis","volume":"314","author":"Schafer","year":"2015","journal-title":"J Am Med Assoc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain."},{"key":"B26","doi-asserted-by":"publisher","first-page":"116990","DOI":"10.1016\/j.jns.2020.116990","article-title":"Clinical characteristics and brain MRI findings in myeloproliferative neoplasms","volume":"416","author":"Nagai","year":"2020","journal-title":"J Neurol Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2014.03.055","article-title":"Platelets and migraine","volume":"134","author":"Danese","year":"2014","journal-title":"Thromb Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000360388","article-title":"Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera","volume":"133","author":"Michiels","year":"2015","journal-title":"Acta Haematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/09537100600758677","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets."},{"key":"B30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(09)70358-8","article-title":"Migraine aura pathophysiology: the role of blood vessels and microembolisation","volume":"9","author":"Dalkara","year":"2010","journal-title":"Lancet Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.amjmed.2019.10.023","article-title":"Aspirin in the treatment and prevention of migraine headaches: possible additional clinical options for primary healthcare providers","volume":"133","author":"Biglione","year":"2020","journal-title":"Am J Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1051093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:09:58Z","timestamp":1670328598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1051093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":31,"alternative-id":["10.3389\/fneur.2022.1051093"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1051093","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"article-number":"1051093"}}